Regenerative medicine company dedicated to developing a functional cure for type 1 diabetes.
ViaCyte is a privately held regenerative medicine company developing novel cell replacement therapies as potential long-term diabetes treatments to achieve glucose control targets and reduce the risk of hypoglycemia and diabetes-related complications. ViaCyte’s product candidates are based on directed differentiation of pluripotent stem cells into PEC-01 pancreatic islet progenitor cells, which are then implanted in durable and retrievable cell delivery devices. ViaCyte demonstrated that when effectively engrafted, PEC-01 cells can mature into glucose-responsive insulin producing cells in patients with type 1 diabetes. To accelerate and expand its efforts, ViaCyte has established collaborative partnerships with leading companies including CRISPR Therapeutics and W.L. Gore & Associates.
Visit website: https://viacyte.com/
Looking Back and Ahead in the Use of Pluripotent Stem Cells in Medicine
Fight Aging! - 14-Dec-2016
Therapies that deliver fresh new stem cell populations will take up the work of lost cells, e.g. ...Read more...
Promising cell therapy for diabetes hidden in seaweed bubble
STAT - 25-Jan-2016
In type 1 diabetes the immune system dismantles the pancreatic cells, known as beta cells, that n...Read more...